| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | CYTODEL INC | 423 W 127TH ST | NEW YORK | NY | 10027-2562 | NEW YORK | USA | R43NS122661 | Recombinant botulinum toxin with improved safety and effectiveness for treatment of dystonia | 000 | 2 | NIH | 3/28/2024 | $0 |
| | 2024 | 2023 | CYTODEL INC | 423 W 127TH ST | NEW YORK | NY | 10027-2562 | NEW YORK | USA | R43NS130849 | Development of B8C1ad as an Orphan Drug for Iatrogenic Botulism | 000 | 1 | NIH | 4/26/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $433,672 ) |
| | 2023 | 2023 | CYTODEL INC | 423 W 127TH ST | NEW YORK | NY | 10027-2562 | NEW YORK | USA | R43NS130849 | Development of B8C1ad as an Orphan Drug for Iatrogenic Botulism | 000 | 1 | NIH | 12/23/2022 | $295,365 |
| | 2023 | 2023 | CYTODEL INC | 423 W 127TH ST | NEW YORK | NY | 10027-2562 | NEW YORK | USA | R43NS122661 | Recombinant botulinum toxin with improved safety and effectiveness for treatment of dystonia | 000 | 2 | NIH | 2/21/2023 | $138,307 |
|
| Issue Date FY: 2022 ( Subtotal = $276,617 ) |
| | 2022 | 2022 | CYTODEL, INC. | 423 W 127TH ST | NEW YORK | NY | 10027-2561 | NEW YORK | USA | R43NS122661 | Recombinant botulinum toxin with improved safety and effectiveness for treatment of dystonia | 000 | 1 | NIH | 3/1/2022 | $276,617 |
|
| Issue Date FY: 2014 ( Subtotal = $223,940 ) |
| | 2014 | 2014 | CYTODEL LLC | 333 W END AVE 12B | NEW YORK | NY | 10023 | NEW YORK | USA | R41NS086115 | Recombinant Botulinum Neurotoxin for Treatment of Spastic Disorders | 000 | 1 | NIH | 8/29/2014 | $223,940 |
|
|
